Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine −

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

Pre-revenue biotech burns through cash, relies on distant government milestones while facing immediate going-concern liquidity crunch.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 18:29 APLI · 0.015 APPILI THERAPEUTICS INC. J
Executive Summary
  • Appili Therapeutics reported FYE 2026 financial results showing a net loss of $4.2 million ($0.03/share), an increase from $2.6 million in the prior year.
  • Cash on hand plummeted to $0.04 million as of March 31, 2026, down from $1.2 million a year earlier, triggering a going concern note due to reliance on future equity and non-dilutive funding.
  • The company secured a US$40 million NIAID contract for the VXV-01 antifungal vaccine, though only a $3.6 million base period is available initially, with options extending to Phase 1.
  • Additional US$14 million in USAFA funding was secured for the ATI-1701 tularemia vaccine candidate.
  • Commercial momentum is noted for LIKMEZ (ATI-1501) in the U.S., generating royalties and milestones.
  • Regulatory progress includes FDA alignment on a bridging strategy for ATI-1801 and successful GMP manufacturing for ATI-1701.
  • Lender extensions on the LZH and Bloom Burton Loans were secured to June/July 2026, contingent on completing an equity financing of at least CAD $350,000 by June 30, 2026.
  • Capitalization stands at 132.3 million common shares, 11.9 million stock options, and 41.4 million warrants.
Material Impact
  • The most recent release confirms a severe liquidity deterioration, with cash reserves effectively exhausted ($0.04M) and a formal going concern warning.
  • While the US$40M NIAID contract and US$14M USAFA funding are strategically significant, they are multi-year, milestone-based, and non-dilutive, meaning they do not provide immediate working capital to cover current burn rates.
  • The contingent requirement to raise CAD $350,000 by June 30, 2026, to avoid loan default underscores an immediate capital need that will likely result in significant equity dilution at the current $0.01 share price.
  • The market has already priced in the government contract news from October 2025 (when the stock briefly spiked to $0.04), and the current earnings release merely confirms the execution of that strategy alongside worsening cash positions.
  • The news is not a fundamental re-rating event; it is a confirmation of the company's ongoing cash burn and dependence on future financing, which is typical for pre-revenue biotechs but remains highly risky.
APLI · Price
Company Overview
  • Appili Therapeutics is a clinical-stage biotechnology company focused on infectious diseases and biodefense.
  • Core initiatives include the development of the VXV-01 antifungal vaccine (NIAID-funded), ATI-1701 tularemia vaccine (USAFA-funded), and ATI-1801 topical antiparasitic for leishmaniasis.
  • The company also commercializes LIKMEZ (ATI-1501), a liquid metronidazole product, through a partnership with Saptalis in the U.S. market.
  • The business model heavily relies on non-dilutive government funding and strategic partnerships to advance its pipeline while minimizing equity dilution.
Read the original news release →

More from APPILI THERAPEUTICS INC. J

Mar 30, 2026 · 07:19

Appili Touts Non-Dilutive Grants as Cash Burn Outpaces Micro-Cap Equity Raises

Other Feb 18, 2026 · 07:19

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Financings Feb 12, 2026 · 18:15

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

Earnings Dec 18, 2025 · 18:34

Appili closes $177,500 first tranche of placement

Financings Dec 18, 2025 · 07:31

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Financings Nov 13, 2025 · 17:21

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

Production / Operations